Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02247739 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor
A Phase 2 study, sponsored by Pharming Technologies B.V..
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT02247739 is a Phase 2 study that has completed, run by Pharming Technologies B.V.. The registered enrollment target is 32 participants.
The verdict
NCT02247739, a Phase 2 study, has completed, sponsored by Pharming Technologies B.V..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
Primary Objective: To evaluate the efficacy of recombinant human C1 inhibitor (rhC1INH) in the prophylaxis of angioedema attacks in patients with HAE Secondary Objective: To evaluate the safety and immunogenicity of recombinant human C1 inhibitor (rhC1INH) in the prophylaxis of angioedema attacks in patients with HAE
Interventions
- OTHER Placebo
- BIOLOGICAL Recombinant human C1 inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02247739
The ClinicalTrials.gov registry entry for NCT02247739 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharming Technologies B.V., which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02247739 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02247739 about?
NCT02247739 is a clinical study titled "A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor". Primary Objective: To evaluate the efficacy of recombinant human C1 inhibitor (rhC1INH) in the prophylaxis of angioedema attacks in patients with HAE Secondary Objective: To evaluate the safety and immunogenicity of recombinant human C1 inhibitor (rhC1INH) in the prophylaxis of angioedema attacks...
What is the current status of trial NCT02247739?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2014-12. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02247739?
The interventions under investigation include: Placebo (OTHER), Recombinant human C1 inhibitor (BIOLOGICAL).
Who is sponsoring clinical trial NCT02247739?
This trial is sponsored by Pharming Technologies B.V., which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.